newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - TIGENIX NV

Okay. It's just about 5 p.m., so I think we can get started. Thanks very much for joining this session. My name's Steve Barker. I cover Japanese healthcare for Jefferies in Japan, and it's my pleasure to be hosting this session with Takeda Pharmaceuticals. We have the CEO, Julie Kim. We also have Andy Plump, head of R&D, and we also have Milano Furuno, CFO. So, everybody, thanks very much for joining us. I'd like to jump straight in with a question for you, Julie. Sure. You know, I think a lot of companies would be excited to even have one blockbuster, something as interesting as a rosé for your Narcolepsy 1 program, but you actually have three very exciting blockbusters coming out. You also have Mim Rilo for Polysthemia Vera, and then very soon you're very likely to get approval for zazacitinib for psoriasis. So how are you preparing to give these three opportunities the attention they deserve? Yeah, so look, we've already launched two of them, and so I would say this. From a total company perspective, we're making sure that we have the right level of resources dedicated to each of these launch assets, and happy to say that both for Mimrylo and Urzaful that have launched. They are doing really well, so very pleased about their performance to date. And as you said, we're waiting for zazocitinib. We do have prior review with the FDA, and we expect to have an answer in March. Okay, that's great. And Andy, I have a question for you around zazacitinab. It's been encouraging to see that there clearly is demand for oral treatments for psoriasis. We've seen that in the market. Do you think dermatologists are ready to, you know, embrace alternatives to the injectables? Well, maybe I'll start, Julian, and I'll hand it over to you and just talk a little bit about the profile of zazocitinib in psoriosis. You know, when we brought this compound in over four years ago, we were excited about the data that we had seen, and every data set that we've revealed since then has just made us even more excited. We actually just had head-to-head data with Ducravacitinib, so it's not really kind of a poised competition for us, but it's a benchmark and it suggests the level of efficacy that we have. It's very unusual to go head-TO-head against another member in the same class. We did that on our primary endpoint, which was 100% skin clearance, we had a two-and-a-half times greater effect. So we saw, just by point estimate, the most significant effects on this endpoint, PASI 100, in any psoriasis trial at week 16, which is about 36 percent. Female Speaker 2 Yeah, and when you look at the oral segment today, and if we just focus on the U.S. market for a moment, the oral segments today represents roughly 10 percent of the overall, and we do believe that there's significant room for that segment to grow. You know, J&J, as you know, has launched last year into the space with an effective oral. We do believe that there's room for more than one oral, and we like Zazo's profile. So in addition to the great data that Andy mentioned, you know we don't have a food restriction for Zazo. Zazo works very well across all patient types within psoriasis, and we have fast onset of activity, of efficacy, strong durability. There's nothing that we are worried about when it comes to Zaza, so we're looking forward to the eventual approval and another launch. And very effective data, as you mentioned, Andy. But where do you see the opportunity with the patients? Is it patients who don't want to have injections for some reason or where's the opportunity? Yeah, so when you look at the progression of patients onto therapy, so first, going onto an injectable is quite a scary thing. But if you have really severe disease, you probably will. But most would like to try an oral first. But the existing oral previously wasn't that effective across patient types. Now they've had an effective oral for one year, and we've seen the pickup of that. And so, again, Zazo as another really effective oral agent, the profile that it has, we think it will do well. Right. Milano, I have a question for you. So three major launches, it's a nice problem to have, but it does require substantial investment up front. I know you have a cost-saving program underway. Could you tell us something about that? How are you funding the investment that these launches require? Yeah, so this year we are already increasing commercial investments. We are planning to invest almost like 100 billion. It's almost the same amount of 100 billion yen for the commercial investment. And it's highly likely we increase a little bit more next year because it's going to be the first full year, launching those three products. In the meantime, we are running a transformation program, the cost savings program, with combining more like strategic organizational change program. We are making basically big change in organizationally. We are de-layering some management layers. We are centralizing some corporate functions. We are leveraging some global capability centers. So making more efficient organization, process standardization, and then getting the savings to fund all those commercial launches. So that's how we are managing the incremental cost investments by the cost savings program. Right. So 100 billion investment this year, going up a little bit next year, but you've got the ongoing savings program, so what I'm hearing is that you should be able to see some profit flowing to the bottom line. in the relatively near future. Yeah, but I think I would be a bit more cautious on that side because, again, we are now launching the three new products, and then, again next year will be the first full year. Okay, first full years. So annualization over the commercial spans. Right. Of course, we do have the savings as well. Savings will be fully annualized the next year. Right. But any launches, you know, you don't see the profit accretive from year one. So that's perhaps still you don'T see the right-of-way kind of profit accreative, but how we are managing those investments and all the savings. Don't forget, and also we are developing the next wave of the new products. So not only the three products launches, but we have a bunch of the phase three programs. That's where we are also increasing investment. That's how you should look at it in the P&L. Right. And, well, that actually brings me to the next question, the stages of growth. You have these three big launches happening right now, but then you have a very exciting pipeline coming up before. You have TAC360 in sleep disorders. You have mezogidamab in autoimmune diseases. You have an oncology program. So how should we be looking? you've talked about the stages of growth. Could you talk specifically about how that relates to these drugs and these programs? Yeah, so a couple of comments, Steve. So when you look at our overall portfolio, so we're not shifting our therapeutic areas, but what we are trying to do is build more depth behind these franchises. So that's not something that we've necessarily had a lot of depth in the past, and that is what we Are focused on. So, when you look at, for example, with Antivio. Now we have AntivIO, we have TAC-299, we have Zazo being developed in IBD, and we will continue to build behind that as well. So that's one comment. And then separately, in terms of the phases of growth that we've laid out for the company, we've talked about Horizon One, where we are transforming the organization, a bit of what Milana was just mentioning, and we have these three launches that will be the start of our new cohort of assets. The rest of our portfolio that is in market is relatively mature, so of course we still have to ensure that that portfolio performs, but it's not going to be a strong driver of future growth. So that's why we said in this Horizon 1 period it'll be low growth. We're going to try to do our best to protect our core operating profit margins. As you heard from Alana, we're going be reinvesting our savings behind the launches and the pipeline development. But all of this will then set us up for Horizon 2 where these first launches will reach scale and then we will start launching the second wave of products. And so that's really what will start creating the longer-term sustainable growth for us. Right. Well, I would like to drill down a little bit into some of the franchises and the broader orexin opportunity. You are the leader with orexins. You already have a Zafel on the market. But you have other assets coming behind, TAT360. Andy, perhaps you could talk to the science. Are you very excited about orexin-2 agonists? Very. So you've asked me to talk about the science, now I'm really excited. So maybe I'll start out, Steve, and just by way of understanding, in a sense, the pyramid of the diseases that we could potentially treat with orexin agonists and start out by defining the underlying biology. So narcolepsy type 1 is different from every other condition where you could potentially use an orexan agonist in that it's a deficiency of orexam. Every other disease that we're talking about, whether it's type 2 narcolepsia, whether its idiopathic hypersomnia, obstructive sleep apnea, whether it's any condition that's characterized by fatigue or attention deficit or you fill in the blank, all of those conditions are characterized by normal erection levels. So the dose in type 1 narcolepsy is much lower, and the consistency of effect, I think, is going to be something that will be somewhat unique to type 1 narcolepsia. Of course, we'll see this as the rest of this plays out. For us, we have orzaful, which is laser-focused on type 1 narcolepsy, And then we have a suite of other molecules. Two are in the clinic right now, 360 and 495. A third will be coming into the clinic. These are all orexin-2 receptor agonists with different properties that we think will play to some of these indications in different ways. And then behind that, we have very substantive effort in the laboratory to come up with next-generation pharmacology, let's say. An example would be interest in the orexid-1 receptor, so dual pharmacology with the orexa-1 receptors. The potential is massive. We have, obviously, the most opportunity in front of us in type 1 narcolepsy, but the potential here is quite significant. That's interesting, Andy. It sounds like you are developing these different compounds targeted for some of these different indications that you mentioned. So there is differences in the way that these drugs are working? There are. So, you know, people always think about potency. Potency ends up being not the least important factor, but a pretty unimportant factor in many respects because the orexin-2 receptor agonists all are generally sufficiently potent. So you have to look at PK. You have to looking at blood-brain barrier penetration off-rate on the receptor. There are just a host of factors that ultimately will play into these molecules. For some indications, we have a fair understanding of what those relationships are to the diseases. In other places, there's a lot of learning. So our intent is to have a range of different molecules that have different features. There's also going to be just a commercial positioning because you're going to be talking about low volume, high price point, like type 1 narcolepsy or type 2 narcolepsy, and then higher volume, lower price point. So if we were to go into, for example, excessive daytime sleepiness across indications or attention deficit or cognition, which is something that these molecules could play in, in many, many indications, that you're talking, obviously, about a very different commercial model. Right. So you've mentioned sleep apnea, attention deficit disorder. There's other companies which are looking at these drugs in depression. It really sounds like there's a very big potential. Yep. So this is a plug for our Capital Markets Day on December 11th. You should all come to Tokyo or get up early and watch us, because we're going to be spending the whole day talking about the evolving strategy under Julie, and a large focus will be on these franchises, including orexin. Right, right. Andy, I have another question for you. So Zasso, hoping to get approval for first indication soon, but you're also developing it for inflammatory bowel disease. You had some interesting data recently. Could you talk to that, please? Sure, so psoriasis launch coming in March, psoriatic arthritis data coming next year, and then phase two data for UC and Crohn's disease will disclose end of the fiscal year. So we shared some just top level comments around the UC study, which read out six weeks ago. We actually have a very robust effect. The effect, and we've talked about this, we haven't provided any specific data, but it's directionally on par with what's been seen by other agents, oral agents in ulcerative colitis, other agents in development. So you can kind of get a sense for what that effect size is. The complexity is that we saw that at the middle dose but not the high dose. Right. So we lost, it's kind of a bell-shaped dose response curve. Two comments about that. One is that that creates a complexity. That's obvious. The second is it's not uncommon with diseases, especially in IBD, but broadly as anti-inflammatory mechanisms, and probably reflects homeostasis within the immune system. As you start to go past a certain threshold, the immune systems often reverses on itself as a protective mechanism. We have some reasons that we think molecularly can explain this, but the explanation will come when we see the Crohn's data, and that will be at the end of the year. We're moving ahead as if we're going to start phase three, so we're doing all of the work that would be necessary, and then once we get the Crohns data, we'll finalize our go go-no-go decision as well as the specifics like dose. Right. But to be clear, you're not disappointed with the data? No, I would say the opposite. I would said when we started the program, we were more enthusiastic mechanistically about a benefit in Crohn's than you see. Right. When we saw these data, it creates a headache that you have this kind of dose response curve. But in terms of what we're seeing at that middle dose, it's very encouraging. So I think it does make the upcoming Crohn'S data particularly important. How will that add to your understanding of this class, this drug, in this indication? Well, if it works, I think we've got a great addition to the armamentarium of oral agents for IBD. Right, right. And so you still, what's the base case? You will develop the drug for both UC and Crohn's? That's right, yeah. Terrific. Okay. So, Milano, back to you. Capital allocation, shareholder returns is always a very important topic. You've got, obviously, an R&D pipeline here to fund. How do you decide on the best use of capital, investing in clinical programs or licensing assets? How do You think about that? Yeah, so our usage of the capital is, you know, the free cash flow-wise, the investment of growth, the leverage, and dividends. Starting from dividend, we have a progressive dividend policy, which means basically either maintain or increase dividends. We want to make some sort of certain predictability on sustained, but long-term sustainable growth on the dividends. That's kind of one portion. If you look at it from a free cash flow perspective, almost like now 40% of the free cash flows is going to the dividends, the other element is in the deal leverage. So we still have a relatively high level of the debt in this industry, like average perspective. the net debt adjusted EBITDA ratio wise we are now 2.5 so we are bringing down from a much higher level so it gives us more flexibility in terms of some firepower but still we want to manage this debt level a little bit lower so before the NTVA biosimilar entry in the US we want to bring it down to two. So that's another element of how we are allocating free cash flow. And then the third one is really important. One is investment for the growth. We are very busy to develop the pipeline. We have pretty good assets on hand. And with all of this, we are quite confident to overcome this NTVO LOE in the future but still we are also open to looking at any opportunities good complementary assets that can give us more depth, what Julie mentioned depth in the therapeutic area of choice then we are happy to make some bolt on, additional licensing acquisition So yeah Yeah, NetDev TV, you're able to write now at about 2.5 times, but you'd like to get it closer to two. You start off at five times, so you've come a long way. So I think arguably you probably do have more flexibility. If you were to consider business development opportunities, I think this is a question for you, Julie, where do you see the biggest opportunities? Clearly you have leading positions in gastroenterology, neuroscience, oncology and BD Decisions it's very important, it really gives you the option of taking the company in a certain direction how do you weigh up the opportunities ahead of you? Yeah, so look we like the areas that we are in today, so this is not about doing an acquisition to enter into a new therapeutic area but as I mentioned we do want to build more depth in these franchises. And so what we are looking for are assets that fit nicely into the spaces that we are trying to develop the deeper pipeline. Our late stage is quite active at the moment across all three areas. So we would be most looking in the earlier stages to fill out that part of the pipeline. Now, of course, if there's something that's really attractive late stage, we will still look, but the focus would be on the earlier stage. Right, so focus on the therapeutic areas that you're in right now and probably earlier stage rather than commercial. Okay, so on that topic of innovation, China has suddenly become a huge source of innovation and you have made use of that. Perhaps you could talk a little bit more about how do you see China developing as a source of innovation for Takeda? Yeah, so look, I think China has become a source of innovation and innovation for the whole industry at this point. I mean, this audience is very well aware that China has evolved from a fast-follow-me-to approach to actually having very exciting, innovative assets. And so for Takeda, this is where we've done a number of deals to bring in assets into our pipeline, and we continue to look at China as an opportunity to identify new assets, but also in terms of how we leverage China in our overall clinical development plan. So, you know, of course, being conscious of the geopolitical tensions that exist, but it is a place where you have to be. Right. Right. Andy, I understand you're heading for retirement next year. You saw the memo. Well, congratulations. I would just love if you could share perhaps your perspective on the time that you've spent at Takeda and beyond. You've had a long career. How has the process of R&D changed over the years? Yeah, it's amazing. Thank you very much, by the way, and thanks for the question. It's been amazing and a privilege, especially the time at Takeda, you know, and it's been great also having a chance to transition with Julie and help with building this next stage for TakedA. You know, I wish I knew what I knew today when I started this job. I bet you would hear that from every R&D head. That would be one thing that I would wish for. But in terms of looking forward, I think, and you and I were talking about this just in the hallway outside, the pace of change in our industry is unlike anything we've ever seen. And I think the biggest challenge, the biggest opportunity is that there's so much that we can do so fast. Science is just taking off, and our ability to translate that science is taking off operationally. Our ability to unravel disease biology, make molecules, the application of AI is fundamentally shifting everything in our business. It is not hype. It's reality. I think the biggest challenge that we face is that because things are going so quickly, our cycle times make programs often irrelevant. So how do we navigate speed? I think that's going to be the biggest challenge and opportunity in our future. Well, I guess that has implications for your BD strategy as well. You don't have time to start from scratch. Yeah. I mean, you've always had to do BD because the success is stochastic in our industry. I think there's another added element of, you know, in some areas, you're going to have to wait. I think you're going to be reluctant to start a program because you just don't know what the pricing landscape will look like, what the competitive landscape will look like. In other areas, I think in areas where you have that leadership edge and that deep vertical expertise I think that's where you want to make investments. Right, okay. So we're running out of time but Julie I'd love if you could just share with us your what you've seen since you became CEO. I mean we've covered a lot of space today. You've got these three big launches. You're got a new pipeline coming through. What opportunities most excite you about Takeda, and where do you think the gap between investors' understanding of Takedan and how you feel about the company? Yeah, so look, I think we have tremendous potential in our pipeline, and these three assets that we've talked about today are just the beginning of that. And I think where the greatest gap is that the question that we get the most is, can Takeda continue to grow beyond Intivio, the LOE that is coming in a number of years? And so this is where we will spend a big part of our Capital Markets Day explaining how we view our ability to continue that growth and have very sustainable growth over the coming horizons. Fantastic. Thank you very much. Thank you. Thank you.

Company
TIGENIX NV
Keywords
TIGENIX NV